Supplementary Figure S14 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity | Synapse
August 1, 2024Open Access
Supplementary Figure S14 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Key Points
Key points are not available for this paper at this time.